$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000121390023080842 Filed on September 29, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$901.9K	$2.310M	$4.136M
YoY Change	181.14%	348.75%	279.61%
Cost Of Revenue	$787.7K	$740.0K	$2.424M
YoY Change	235.14%	179.2%	343.97%
Gross Profit	$21.24K	$1.570M	$1.403M
YoY Change	-104.33%	528.7%	158.13%
Gross Profit Margin	2.36%	67.97%	33.93%
Selling, General & Admin	$1.300M	$1.410M	$5.850M
YoY Change	-16.69%	-19.08%	-12.25%
% of Gross Profit	6119.95%	89.81%	416.95%
Research & Development	$1.292M	$620.0K	$3.732M
YoY Change	-6.28%	-58.69%	-48.75%
% of Gross Profit	6082.73%	39.49%	266.0%
Depreciation & Amortization	$54.83K	$50.00K	$202.2K
YoY Change	11.79%	-7.39%	8.94%
% of Gross Profit	258.13%	3.18%	14.42%
Operating Expenses	$2.694M	$2.090M	$9.782M
YoY Change	-9.84%	-36.61%	-45.07%
Operating Profit	-$2.537M	-$520.0K	-$7.948M
YoY Change	-27.73%	-82.94%	-57.27%
Interest Expense	$90.00K	$180.0K	$440.0K
YoY Change	-471.9%	-603.64%	-2150.33%
% of Operating Profit
Other Income/Expense, Net	$136.0K		$431.2K
YoY Change	106.79%		-132.81%
Pretax Income	-$2.537M	-$340.0K	-$7.935M
YoY Change	-27.59%	-95.68%	-57.34%
Income Tax		$0.00	$13.10K
% Of Pretax Income
Net Earnings	-$2.500M	-$340.0K	-$7.948M
YoY Change	-28.78%	-95.68%	-57.27%
Net Earnings / Revenue	-277.2%	-14.72%	-192.18%
Basic Earnings Per Share	-$0.76		-$3.25
Diluted Earnings Per Share	-$0.76	-$0.10	-$3.25
COMMON SHARES
Basic Shares Outstanding	3.328M shares	3.328M shares	2.448M shares
Diluted Shares Outstanding	3.328M shares		2.448M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.780M	$8.960M	$8.960M
YoY Change	-27.82%	44.01%	44.01%
Cash & Equivalents	$6.738M	$8.913M	$8.910M
Short-Term Investments	$40.00K	$40.00K	$40.00K
Other Short-Term Assets	$220.0K	$500.0K	$500.0K
YoY Change	-38.32%	-37.28%	-37.28%
Inventory	$1.133M	$1.616M	$1.620M
Prepaid Expenses
Receivables	$165.9K	$260.4K	$260.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.295M	$11.33M	$11.33M
YoY Change	-28.14%	18.07%	18.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$615.1K	$723.4K	$720.0K
YoY Change	-23.35%	-20.0%	-20.38%
Goodwill
YoY Change
Intangibles		$1.946M
YoY Change		-7.71%
Long-Term Investments
YoY Change
Other Assets	$101.8K	$104.9K	$100.0K
YoY Change	-40.52%	-40.61%	-43.39%
Total Long-Term Assets	$2.622M	$2.775M	$2.780M
YoY Change	-13.79%	-13.02%	-12.85%
TOTAL ASSETS
Total Short-Term Assets	$8.295M	$11.33M	$11.33M
Total Long-Term Assets	$2.622M	$2.775M	$2.780M
Total Assets	$10.92M	$14.11M	$14.11M
YoY Change	-25.14%	10.31%	10.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$380.0K	$540.0K	$540.0K
YoY Change	-65.34%	-53.69%	-53.69%
Accrued Expenses	$960.0K	$1.440M	$1.440M
YoY Change	-42.52%	-12.91%	-12.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.339M	$2.001M	$2.000M
YoY Change	-59.19%	-39.73%	-39.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$20.00K	$20.00K
YoY Change	-100.0%	-94.87%	-94.87%
Total Long-Term Liabilities	$0.00	$20.00K	$20.00K
YoY Change	-100.0%	-94.87%	-94.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.339M	$2.001M	$2.000M
Total Long-Term Liabilities	$0.00	$20.00K	$20.00K
Total Liabilities	$1.339M	$2.017M	$2.020M
YoY Change	-62.55%	-45.63%	-45.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.9M	-$101.4M
YoY Change	7.15%	8.5%
Common Stock	$113.4M	$77.62M
YoY Change	56.03%	9.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.578M	$12.09M	$12.09M
YoY Change
Total Liabilities & Shareholders Equity	$10.92M	$14.11M	$14.11M
YoY Change	-25.14%	10.31%	10.34%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$2.500M	-$340.0K	-$7.948M
YoY Change	-28.78%	-95.68%	-57.27%
Depreciation, Depletion And Amortization	$54.83K	$50.00K	$202.2K
YoY Change	11.79%	-7.39%	8.94%
Cash From Operating Activities	-$2.174M	-$650.0K	-$7.283M
YoY Change	-3.61%	-83.94%	-53.26%
INVESTING ACTIVITIES
Capital Expenditures		$160.0K	$160.0K
YoY Change			309.16%
Acquisitions			$500.0K
YoY Change
Other Investing Activities	$0.00	$130.0K	$1.790K
YoY Change		-117.92%	-100.28%
Cash From Investing Activities		-$30.00K	-$661.8K
YoY Change		-95.86%	-1.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.00M
YoY Change			-30.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$10.68M
YoY Change		-100.0%	-29.13%
NET CHANGE
Cash From Operating Activities	-$2.174M	-650.0K	-$7.283M
Cash From Investing Activities		-30.00K	-$661.8K
Cash From Financing Activities		0.000	$10.68M
Net Change In Cash	-$2.174M	-680.0K	$2.736M
YoY Change	-168.51%	-344.12%	-330.61%
FREE CASH FLOW
Cash From Operating Activities	-$2.174M	-$650.0K	-$7.283M
Capital Expenditures		$160.0K	$160.0K
Free Cash Flow		-$810.0K	-$7.443M
YoY Change		-79.99%	-52.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	inm	Acquisition Consideration Payable AcquisitionConsiderationPayable		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39685
CY2023	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 310 – 815 W Hastings
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 1B4
CY2023	dei	City Area Code CityAreaCode	(604)
CY2023	dei	Local Phone Number LocalPhoneNumber	669-7207
CY2023	dei	Security12b Title Security12bTitle	Common Stock, no par value
CY2023	dei	Trading Symbol TradingSymbol	INM
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets		usd
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	3180248	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3328191	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	New York
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8912517	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6176866	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	44422	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	44804	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	260399	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88027	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2490854	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	498033	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	797225	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11331727	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9597776	usd
CY2023Q2	inm	Property Equipment And Rou Assets Net PropertyEquipmentAndROUAssetsNet	723426	usd
CY2022Q2	inm	Property Equipment And Rou Assets Net PropertyEquipmentAndROUAssetsNet	904252	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2108915	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104908	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176637	usd
CY2023Q2	us-gaap	Assets Assets	14106340	usd
CY2022Q2	us-gaap	Assets Assets	12787580	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2415265	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	404276	usd
CY2023Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16171	usd
CY2022Q2	inm	Acquisition Consideration Payable AcquisitionConsiderationPayable	500000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2000619	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3319541	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389498	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2016613	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3709039	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	650667	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	650667	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	70718461	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35741115	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31684098	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400209	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93452587	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14106340	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12787580	usd
CY2023	us-gaap	Revenues Revenues	4135561	usd
CY2022	us-gaap	Revenues Revenues	1089435	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2423588	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	545889	usd
CY2023	inm	Inventory Writedown InventoryWritedown	308937	usd
CY2023	us-gaap	Gross Profit GrossProfit	1403036	usd
CY2022	us-gaap	Gross Profit GrossProfit	543546	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3732056	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7282615	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5847518	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6867030	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	202249	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	185657	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3472593	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9781823	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17807895	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	492440	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	96090	usd
CY2022	inm	Warrant Modification Expense WarrantModificationExpense	1314307	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-48175	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-117551	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7934522	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18600117	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13100	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18600117	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.25
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-33.17
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2448458	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	560829	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2023	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	11999790	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2011266	usd
CY2023	inm	Adjustments To Additional Paid In Agents Investment Options AdjustmentsToAdditionalPaidInAgentsInvestmentOptions	691483	usd
CY2023	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	646	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	278155	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7376567	usd
CY2022	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	11999686	usd
CY2022	inm	Atm Offering Net Of Issuance Costs ATMOfferingNetOfIssuanceCosts	146533	usd
CY2022	inm	Registered Direct And Private Placement RegisteredDirectAndPrivatePlacement	4999580	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2882015	usd
CY2022	inm	Adjustments To Additional Paid In Agents Warrants AdjustmentsToAdditionalPaidInAgentsWarrants	739920	usd
CY2022	inm	Adjustments To Additional Paid In Agents Investment Options AdjustmentsToAdditionalPaidInAgentsInvestmentOptions	192492	usd
CY2022	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	315	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3013500	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	79879	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1314307	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18600117	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	697894	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18600117	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	202249	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	185657	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	278155	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	697894	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79879	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	393748	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	326133	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11355	usd
CY2023	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	803	usd
CY2022	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	115	usd
CY2023	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	1183	usd
CY2022	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	1770	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3472593	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	46775	usd
CY2022	inm	Warrant Modification Expenses WarrantModificationExpenses	1314307	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-565561	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2003732	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-299192	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-190661	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	61432	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	219147	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40008	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-806530	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-811599	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16171	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5142	usd
CY2023	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	426575	usd
CY2022	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	341862	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7283199	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15583758	usd
CY2022	inm	Cash Acquired From Acqusition CashAcquiredFromAcqusition	91566	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	500000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	300457	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1790	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	160014	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39108	usd
CY2023	inm	Sale Of Shortterm Investments SaleOfShorttermInvestments	-42268	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	42268	usd
CY2022	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	425000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-661804	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-672999	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000436	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17146114	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1319782	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1784791	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	290826	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10680654	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15070497	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2735651	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1186260	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7363126	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2023	inm	Preferred Investment Options To Its Placement Agent PreferredInvestmentOptionsToItsPlacementAgent	691484	usd
CY2022	inm	Preferred Investment Options To Its Placement Agent PreferredInvestmentOptionsToItsPlacementAgent	192491	usd
CY2022	inm	Shortterm Loan ShorttermLoan	-739920	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	3013500	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">Through June 30, 2023, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $7.9 million and $18.6 million for the years ended June 30, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of approximately $101.4 million at June 30, 2023. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of the issuance date of these consolidated annual financial statements, the Company expects its cash, cash equivalents and short-term investments of $9.0 million as of June 30, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of calendar 2024, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the health & wellness sector as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These consolidated financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i>COVID-19 Impacts</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s consolidated financial statements as of and for the and for the year ended June 30, 2023, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</p>
CY2023	us-gaap	Profit Loss ProfitLoss	7900000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	18600000	usd
CY2023Q2	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	101400000	usd
CY2023Q2	us-gaap	Cash Cash	9000000	usd
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and warrant valuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">Actual results could differ from those estimates.</p>
CY2023Q2	inm	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1946279	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	20000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation (CDIC) insurable limits. The Company has not experienced any losses related to these balances. The uninsured cash balance as of June 30, 2023, was $3.8 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s customers are primarily concentrated in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of June 30, 2023, we had three customers with an accounts receivable balance representing 41%, 30% and 15% of total accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the year ended June 30, 2023, the Company had four customers that accounted for 22%, 17%, 16% and 11% of revenue. For the year ended June 30, 2022, the Company had three customer that accounted for 21%, 20%, and 11% of revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3800000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	93820	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	82000	shares
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2022	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	1449554	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2023039	usd
CY2021Q4	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	1000000	usd
CY2023Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss		usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3619171	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	560731	shares
CY2022Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	839638	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	542305	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	139120	usd
CY2023Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P12M
CY2023Q2	inm	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	357664	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	292577	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	514113	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1724851	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893506	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	473426	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2490854	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2023Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings	93820	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1648747	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1420722	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925321	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	516470	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	723426	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	904252	usd
CY2023	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	39613	usd
CY2022	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	26426	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	369239	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	289594	usd
CY2022Q2	us-gaap	Goodwill Gross GoodwillGross	2023039	usd
CY2022Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	216000	usd
CY2022Q2	inm	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	270439	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2415265	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2108915	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1946279	usd
CY2022Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	2000000	usd
CY2022	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	1200000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	200000	usd
CY2023Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2022Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2022Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	981141	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	818505	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1946279	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2108915	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	159228	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	158935	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	158935	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	158935	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	158935	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	158935	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1151604	usd
CY2021Q4	us-gaap	Loans Receivable Fair Value Disclosure LoansReceivableFairValueDisclosure	425000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1365755	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-19260014	usd
CY2023	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma	-34.34
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	560829	shares
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	544179	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1166068	usd
CY2023Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	164587	usd
CY2022Q3	inm	Total Common Share Value TotalCommonShareValue	410376	usd
CY2022Q4	inm	Total Common Share Value TotalCommonShareValue	263372	usd
CY2020Q3	inm	Total Common Share Value TotalCommonShareValue	1459051	usd
CY2022Q2	inm	Total Common Share Value TotalCommonShareValue	754072	usd
CY2022Q2	inm	Prefunded Warrants PrefundedWarrants	69930	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1499999	usd
CY2023	inm	Prefunded Warrant PrefundedWarrant	2269430	shares
CY2022	inm	Prefunded Warrant PrefundedWarrant	293952	shares
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
CY2021Q3	inm	Ipo Warrant Issue IPOWarrantIssue	161453	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	71.2
CY2021Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	18.5
CY2022Q2	inm	Warrant Expiry Date WarrantExpiryDate	2029-06-06
CY2021Q3	inm	Warrants Modification Expense WarrantsModificationExpense	1194752	usd
CY2017Q1	inm	Issued And Outstanding Percentage IssuedAndOutstandingPercentage	0.20	pure
CY2023	inm	Issued And Outstanding Percentage IssuedAndOutstandingPercentage	0.20	pure
CY2021Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	36472	shares
CY2021Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price At Beginning SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAtBeginning	215.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	31160	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	12029	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	122.38
CY2022Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	55603	shares
CY2022Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price At Ending SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAtEnding	128.59
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	61720	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14681	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	267.13
CY2023Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	102642	shares
CY2023Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price At Ending SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAtEnding	31.28
CY2022	inm	Number Of Vested And Exercisable NumberOfVestedAndExercisable	26182	shares
CY2022	inm	Weighted Average Exercise Price Vested And Exercisable WeightedAverageExercisePriceVestedAndExercisable	228.87
CY2022	inm	Number Of Unvested NumberOfUnvested	29421	shares
CY2022	inm	Weighted Average Exercise Price Unvested WeightedAverageExercisePriceUnvested	39.35
CY2023	inm	Number Of Vested And Exercisable NumberOfVestedAndExercisable	51067	shares
CY2023	inm	Weighted Average Exercise Price Vested And Exercisable WeightedAverageExercisePriceVestedAndExercisable	57.44
CY2023	inm	Number Of Unvested NumberOfUnvested	51575	shares
CY2023	inm	Weighted Average Exercise Price Unvested WeightedAverageExercisePriceUnvested	5.38
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.85
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	21.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0374	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0117	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y3M18D
CY2023	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	1.2298	pure
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.9715	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	inm	Weighted Average Forfeiture Rate WeightedAverageForfeitureRate	0.05	pure
CY2022	inm	Weighted Average Forfeiture Rate WeightedAverageForfeitureRate	0.05	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	278154	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	697894	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	51575	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y7M6D
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	384713	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9017	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2023	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	391707	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	553392	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	241270	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	248254	usd
CY2023Q2	inm	Deferred Income Tax Lease Liability DeferredIncomeTaxLeaseLiability	98827	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18600117	usd
CY2023	inm	Effective Income Tax Rate Reconciliation Income Tax Expenserecovery At The Statutory Rate EffectiveIncomeTaxRateReconciliationIncomeTaxExpenserecoveryAtTheStatutoryRate	-2073116	usd
CY2022	inm	Effective Income Tax Rate Reconciliation Income Tax Expenserecovery At The Statutory Rate EffectiveIncomeTaxRateReconciliationIncomeTaxExpenserecoveryAtTheStatutoryRate	-4710669	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2532867	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4112045	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	9638	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-220491	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	76605	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	613269	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	417194	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	591263	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	553877	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	582548	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	396211	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-197131	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	13100	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	67875659	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	62921785	usd
CY2023	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	4295287	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	3328922	usd
CY2023Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19490270	usd
CY2022Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	17003766	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1265542	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	702479	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	11638	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	193549	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	131714	usd
CY2022Q2	inm	Deferred Income Tax Lease Liability DeferredIncomeTaxLeaseLiability	51994	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	21239261	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18753434	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	119889	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	16546	usd
CY2023Q2	inm	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	91377	usd
CY2022Q2	inm	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	55260	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	211266	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	71806	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21027995	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18681628	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21027995	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18681628	usd
CY2023	inm	Recognized Tax Benefits RecognizedTaxBenefits	0.50	pure
CY2023	us-gaap	Revenues Revenues	4135561	usd
CY2022	us-gaap	Revenues Revenues	1089435	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2423588	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	545889	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9781823	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17807895	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	431165	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1335768	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7947622	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18600117	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8912517	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6176866	usd
CY2023Q2	inm	Cost Of Services Directs Materials CostOfServicesDirectsMaterials	2	usd
CY2023	us-gaap	Cost Direct Material CostDirectMaterial	0.7	usd
CY2023	inm	Investment Term InvestmentTerm	P1Y
CY2023Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44422	usd
CY2022Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44676	usd
CY2023	inm	Warrants To Purchase WarrantsToPurchase	700	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	700	shares
CY2023	inm	Agreement Amount AgreementAmount	300000	usd
	us-gaap	Legal Fees LegalFees	345935	usd
CY2023	us-gaap	Legal Fees LegalFees	634208	usd
CY2023Q3	us-gaap	Share Price SharePrice	1
CY2022	inm	Inventory Writedown InventoryWritedown		usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023	inm	Warrant Modification Expense WarrantModificationExpense		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023	inm	Warrant Modification Expenses WarrantModificationExpenses		usd
CY2023	inm	Cash Acquired From Acqusition CashAcquiredFromAcqusition		usd
CY2023	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	inm	Shortterm Loan ShorttermLoan		usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate		usd
CY2022Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
inm-20230630_cal.xml	Edgar Link	unprocessable
0001213900-23-080842-index-headers.html	Edgar Link	pending
0001213900-23-080842-index.html	Edgar Link	pending
0001213900-23-080842.txt	Edgar Link	pending
0001213900-23-080842-xbrl.zip	Edgar Link	pending
f10k2023ex10-13_inmedpharma.htm	Edgar Link	pending
f10k2023ex21-1_inmedpharma.htm	Edgar Link	pending
f10k2023ex23-1_inmedpharma.htm	Edgar Link	pending
f10k2023ex23-2_inmedpharma.htm	Edgar Link	pending
f10k2023ex31-1_inmedpharma.htm	Edgar Link	pending
f10k2023ex31-2_inmedpharma.htm	Edgar Link	pending
f10k2023ex32-1_inmedpharma.htm	Edgar Link	pending
f10k2023ex32-2_inmedpharma.htm	Edgar Link	pending
f10k2023ex4-13_inmedpharma.htm	Edgar Link	pending
f10k2023_inmedpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
inm-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
inm-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
inm-20230630_pre.xml	Edgar Link	unprocessable
inm-20230630_lab.xml	Edgar Link	unprocessable
f10k2023_inmedpharma_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2023 Q3 Form 10-K Financial Statement

#000121390023080842 Filed on September 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2023 Q3 Form 10-K Financial Statement

#000121390023080842 Filed on September 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm